tiprankstipranks
Trending News
More News >
Actinium Pharmaceuticals (ATNM)
:ATNM

Actinium Pharmaceuticals (ATNM) AI Stock Analysis

Compare
2,222 Followers

Top Page

AT

Actinium Pharmaceuticals

(NYSE MKT:ATNM)

Rating:41Neutral
Price Target:
Actinium Pharmaceuticals faces substantial financial challenges due to declining revenues, net losses, and negative cash flows, contributing to a low overall score. The technical analysis suggests a bearish trend, with the stock trading below key moving averages and negative MACD. The valuation is further weakened by a negative P/E ratio and absence of dividends. These factors significantly impact the stock's attractiveness, resulting in a score towards the lower end of the scale.
Positive Factors
Collaboration and Research
Actinium recently entered into a research agreement with Memorial Sloan Kettering Cancer Center to further develop Actimab-A.
Efficacy of ATNM-400
Recent preclinical data for ATNM-400 in prostate cancer has demonstrated promising results, outperforming existing treatments and showing robust antitumor activity.
Financial Stability
Management stated that the current cash runway now extends into 2028, providing financial stability for future developments.
Negative Factors
Financial Performance
Actinium reported a net loss of $15.9 million, which included a significant one-time non-cash charge related to the cancellation of stock options.
Limited Treatment Options
The new preclinical data on ATNM-400 is highly encouraging due to the limited treatment options for patients who have progressed after PSMA-targeted therapies.

Actinium Pharmaceuticals (ATNM) vs. SPDR S&P 500 ETF (SPY)

Actinium Pharmaceuticals Business Overview & Revenue Model

Company DescriptionActinium Pharmaceuticals (ATNM) is a biopharmaceutical company specializing in the development of targeted therapies for patients with unmet needs in oncology. The company primarily focuses on developing radioimmunotherapy and other innovative treatments that leverage its expertise in radioisotopes and antibody technology. Actinium's core products are centered around its proprietary Antibody Radiation-Conjugate (ARC) platform, which aims to deliver potent radiation directly to cancer cells while sparing healthy tissue.
How the Company Makes MoneyActinium Pharmaceuticals generates revenue through a combination of partnerships, licensing agreements, and potentially, future sales of its developed therapies. The company's revenue model primarily involves collaborations with larger pharmaceutical companies to co-develop and commercialize its proprietary therapies. These partnerships often include upfront payments, milestone payments, and royalties based on the successful development and commercialization of its drug candidates. Actinium's focus on advancing its pipeline through clinical trials also positions it to earn revenue from the eventual approval and sale of its therapeutic products. Additionally, the company may engage in research and development agreements with academic and research institutions to further its scientific initiatives.

Actinium Pharmaceuticals Financial Statement Overview

Summary
Actinium Pharmaceuticals faces significant financial challenges with declining revenues, substantial net losses, and negative cash flows. While the balance sheet shows low leverage, the company's ability to generate revenue and positive cash flows remains a key concern. Continued reliance on external financing poses risks if not managed carefully.
Income Statement
15
Very Negative
Actinium Pharmaceuticals shows a negative revenue growth trajectory with declining revenues over the years, zero revenue in the latest report, and consistent net losses. Profitability metrics, such as net profit margin, are negative due to significant operating losses and no gross profit, indicating high operational costs relative to revenue.
Balance Sheet
45
Neutral
The company has a low debt-to-equity ratio, suggesting a low reliance on debt financing, which is positive. However, the persistent negative net income affects the return on equity (ROE), making it negative. The equity ratio is relatively stable, indicating a moderate level of equity funding compared to total assets.
Cash Flow
30
Negative
Operating cash flow is consistently negative, reflecting ongoing cash outflows from operations. The free cash flow is also negative, indicating that the company is not generating enough cash to cover its capital expenditures. Despite this, there is a significant reliance on financing activities to sustain operations.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue0.000.0081.00K1.03M1.14M0.00
Gross Profit-189.00K0.0081.00K331.00K620.00K-447.00K
EBITDA-48.57M-37.43M-51.13M-33.41M-24.44M-21.77M
Net Income-45.51M-38.24M-48.82M-33.02M-24.58M-22.04M
Balance Sheet
Total Assets68.65M76.90M81.44M114.19M80.39M66.40M
Cash, Cash Equivalents and Short-Term Investments65.33M72.90M76.68M108.91M77.83M63.56M
Total Debt1.43M1.57M2.11M2.58M310.00K738.00K
Total Liabilities42.95M44.14M45.07M47.71M6.84M5.08M
Stockholders Equity25.69M32.76M36.38M66.48M73.55M61.32M
Cash Flow
Free Cash Flow-33.27M-33.08M-47.49M8.28M-21.00M-21.87M
Operating Cash Flow-33.27M-33.07M-47.34M8.64M-20.87M-21.62M
Investing Cash Flow0.00-11.00K-153.00K-366.00K-133.00K-253.00K
Financing Cash Flow14.55M29.32M14.87M23.11M35.22M76.18M

Actinium Pharmaceuticals Technical Analysis

Technical Analysis Sentiment
Negative
Last Price1.43
Price Trends
50DMA
1.55
Negative
100DMA
1.41
Positive
200DMA
1.46
Negative
Market Momentum
MACD
-0.04
Positive
RSI
44.01
Neutral
STOCH
8.45
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATNM, the sentiment is Negative. The current price of 1.43 is below the 20-day moving average (MA) of 1.58, below the 50-day MA of 1.55, and below the 200-day MA of 1.46, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 44.01 is Neutral, neither overbought nor oversold. The STOCH value of 8.45 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ATNM.

Actinium Pharmaceuticals Risk Analysis

Actinium Pharmaceuticals disclosed 59 risk factors in its most recent earnings report. Actinium Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Actinium Pharmaceuticals Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
53
Neutral
$45.19M-60.44%-76.29%
51
Neutral
$7.55B0.30-61.90%2.27%17.11%1.58%
51
Neutral
$68.41M81.15%99.47%
50
Neutral
$55.77M-119.22%25.51%
47
Neutral
$53.51M-67.86%0.34%6.20%
41
Neutral
$42.11M-130.87%-100.00%30.65%
35
Underperform
$71.90M-83.37%28.92%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
ATNM
Actinium Pharmaceuticals
1.43
-5.54
-79.48%
PDSB
PDS Biotechnology
1.27
-1.85
-59.29%
ARMP
Armata Pharmaceuticals
1.94
-0.73
-27.34%
ALGS
Aligos Therapeutics
7.31
-2.79
-27.62%
HYPR
Hyperfine
0.72
-0.28
-28.00%
ANEB
Anebulo Pharmaceuticals
1.81
-0.78
-30.12%

Actinium Pharmaceuticals Corporate Events

Executive/Board ChangesShareholder Meetings
Actinium Pharmaceuticals 2024 Stockholder Meeting Outcomes
Neutral
Nov 27, 2024

Actinium Pharmaceuticals, Inc. held its 2024 annual stockholder meeting where Sandesh Seth and Jeffrey W. Chell were re-elected as Class II directors to serve until 2027. Additionally, Marcum LLP was ratified as the independent public accountant for the fiscal year 2024. The meeting saw the participation of 19,724,287 shares, with all proposals receiving approval from stockholders.

Executive/Board ChangesBusiness Operations and Strategy
Actinium Pharmaceuticals Strengthens Board with New Appointment
Positive
Nov 5, 2024

Actinium Pharmaceuticals has appointed Dr. June Almenoff, a seasoned biopharma executive with over 25 years of experience in drug development and leadership, to its Board of Directors. Dr. Almenoff’s extensive background in translational medicine and business development, including leading successful product approvals, is expected to bolster Actinium’s strategic vision and innovation in targeted radiotherapies. Her expertise will be invaluable as Actinium aims to enhance its position in the radiopharmaceutical sector, focusing on innovative treatments for oncology patients.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 26, 2025